This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Galectin-1 (LGALS1)	<p>Cell culture studies suggest that inhibiting LGALS1 could help treat Epstein-Barr virus (EBV)-associated lymphoma, which can result from immunosuppression used in transplantation procedures. In cultured EBV-specific cytotoxic T cells, an LGALS1 human mAb prevented apoptosis compared with control antibody. Next steps include testing the LGALS1 antibody in additional cancers and in mouse models of post-transplant lymphoproliferative diseases.</p> <p>SciBX 4(9); doi:10.1038/scibx.2011.251 Published online March 3, 2011</p>	Patent application filed; available for licensing	<p>Ouyang, J. <i>et al. Blood</i>; published online Feb. 7, 2011; doi:10.1182/blood-2010-11-320481</p> <p>Contact: Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, Mass. e-mail: margaret_shipp@dfci.harvard.edu</p>